| Literature DB >> 35898198 |
Kieran Seay1, Bethany Bustamante1, Alexander Truskinovsky2, Andrew Menzin1, Gary L Goldberg1.
Abstract
Objective: Intestinal type mucinous adenocarcinoma (iMACE) is a rare and unusual variant of mucinous carcinoma of the endometrium that can show focal features of poorly differentiated adenocarcinomas of gastric, pancreatic or intestinal origin by producing signet ring cells. To date, only two reported cases of signet ring cells as a morphological feature of iMACE have been reported. Alterations in E-cadherin expression have been linked to increased metastatic potential, tumor dedifferentiation, and deep myometrial invasion in endometrial carcinomas. The presence or absence of E-cadherin in iMACE with signet-ring cells has not been studied. Thus, we sought to analyze E-cadherin expression in this aggressive variant of endometrial carcinoma. Cases: Diagnosis of iMACE with signet ring cells was rendered with the aid of immunohistochemical staining and histological analysis. Average age of diagnosis was 72 with the presenting complaint of postmenopausal bleeding in all three women. Focal loss or weakly positive E-cadherin expression was seen in areas of signet-rings cell morphology in all three cases.Entities:
Keywords: E-cadherin; Endometrium; Intestinal differentiation; Signet-rings morphology
Year: 2022 PMID: 35898198 PMCID: PMC9309656 DOI: 10.1016/j.gore.2022.101046
Source DB: PubMed Journal: Gynecol Oncol Rep ISSN: 2352-5789
Fig. 1(a–e) Case A. (a) Hematoxylin and eosin-stained section shows focal signet ring cell carcinoma (asterisk) surrounded by moderately differentiated mucinous adenocarcinoma, morphologically compatible with the intestinal type (original magnification x200). Both components of the adenocarcinoma are positive for cytokeratin 7 (b) and cytokeratin 20 (c) (both original magnifications x100). (d) Both components of the adenocarcinoma are positive for CDX2 (original magnification x200). (e) The signet ring cell component of the carcinoma is focally, very weakly positive for E-cadherin (original magnification x200). (f–j) Case B. (f) Hematoxylin and eosin-stained section shows focal signet ring cell carcinoma (asterisk). The signet ring cell component is focally, weakly positive for cytokeratin 7 (g) and cytokeratin 20 (h), and diffusely positive for CDX2 (i). (j) The signet ring cell carcinoma is focally, very weakly positive for E-cadherin (asterisk). All original magnifications x200. (k–o) Case C. (k) Hematoxylin and eosin-stained section shows a prominent signet ring cell component of the adenocarcinoma, more abundant than in the previous two cases, showing high-grade nuclear atypia. The carcinoma is negative for cytokeratin 7 (l) and positive for cytokeratin 20 (m), showing a colorectal or appendiceal immunophenotype. (n) The tumor is positive for CDX2. (o) The signet ring cell carcinoma is completely negative for E-cadherin. All original magnifications x200. In all three cases, the signet ring cell component of the adenocarcinoma was negative for PAX8 and estrogen receptors (not shown).
Summary of Immunohistochemical Results.
| IHC | |||
|---|---|---|---|
| CK20 | + | + | Focally weak |
| CDX2 | + | Focally positive | + |
| CK7 | + | – | – |
| PAX-8 | Focally weak | – | – |
| ER | – | – | – |
| E-Cadherin | Focally weakly positive | Focally weakly positive | – |
Literature review of intestinal type mucinous adenocarcinoma.
| Case | Age, presenting symptom | Surgery | FIGO stage | Adjuvant | MMR | FU |
|---|---|---|---|---|---|---|
| 80, PMB | H + BSO + PLND | IVB | Declined | Intact | DOD @11 months | |
| 63, PMB | H + BSO + PLND | IIIA | Declined | Intact | NED @36 months | |
| 73, PMB | H + LSO + PLND | 4A | Declined | MSI stable | DOD@ 6 months after surgery | |
| 49, PMB, PP | H + BSO + PLND | IVB | NCHT: Carboplatin, Paclitaxel | Loss: MSH2 | ALD @6 months | |
| 58, NR | H + BSO + PLND | IA | EBRT, VBT | NR | Vaginal and vulvar recurrences. NED@ 87 months | |
| 62, PMB | H + BSO + PLND | IA | NRc | Loss: MLH1 | Peritoneal recurrence. DOD @21 months | |
| 81, PMB | H + BSO | IIIA | Declined | NR | NR | |
| 55, PMB | H + BSO | IA | NRc | NR | NR | |
| NR | NR | NR | NR | NR | NR | |
| NR | NR | NR | NR | NR | NR | |
| 71, PMB | H + BSO + PLND + PALD + OB + AP | IIIC | PRT | NR | Peritoneal recurrence | |
| 72, PMB | H + BSO | IA | NR | IA | NED |
FU: follow up; LUS: lower uterine segment; PMB: post-menopausal bleeding; DOD: Dead of disease; NR: not reported; NRc: Not recommended; H: hysterectomy; BSO: bilateral salpingo-oophorectomy PLND: pelvic lymph node dissection; PALD: para-aortic lymphadenectomy; OB: omental biopsy; AP: appendectomy; MHI-H: high-grade microsatellite instability; NCHT: neoadjuvant, chemotherapy; PRT: pelvic radiation therapy; EBRT: external bean radiation therapy; VBT: vaginal brachytherapy; NED: No evidence of disease.